RU98100114A - USE OF NEURO-DERIVATED EMBRYONIC CELL LINES FOR TRANSPLANTATION THERAPY - Google Patents

USE OF NEURO-DERIVATED EMBRYONIC CELL LINES FOR TRANSPLANTATION THERAPY

Info

Publication number
RU98100114A
RU98100114A RU98100114/14A RU98100114A RU98100114A RU 98100114 A RU98100114 A RU 98100114A RU 98100114/14 A RU98100114/14 A RU 98100114/14A RU 98100114 A RU98100114 A RU 98100114A RU 98100114 A RU98100114 A RU 98100114A
Authority
RU
Russia
Prior art keywords
cell line
line according
nucleic acid
biologically active
active peptide
Prior art date
Application number
RU98100114/14A
Other languages
Russian (ru)
Other versions
RU2234338C2 (en
Inventor
Еуджин О. Мэйджор
Карло С. Торнаторе
Гал Ядид
Original Assignee
Правительство Соединенных Штатов Америки, представленное Секретарем Департамента Здравоохранения и Обслуживания Человека
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/467,958 external-priority patent/US5753491A/en
Application filed by Правительство Соединенных Штатов Америки, представленное Секретарем Департамента Здравоохранения и Обслуживания Человека filed Critical Правительство Соединенных Штатов Америки, представленное Секретарем Департамента Здравоохранения и Обслуживания Человека
Publication of RU98100114A publication Critical patent/RU98100114A/en
Application granted granted Critical
Publication of RU2234338C2 publication Critical patent/RU2234338C2/en

Links

Claims (16)

1. Иммортализованная нейро-производная эмбриональная клеточная линия человека, отличающаяся тем, что она включает в себя ксеногенную последовательность нуклеиновой кислоты, причем указанная клеточная линия способна к экспрессии указанной ксеногенной последовательности нуклеиновой кислоты.1. An immortalized neuro-derivative human embryonic cell line, characterized in that it includes a xenogenic nucleic acid sequence, said cell line being capable of expressing said xenogenic nucleic acid sequence. 2. Клеточная линия по п. 1, отличающаяся тем, что она представляет собой глиальную клеточную линию. 2. The cell line according to claim 1, characterized in that it is a glial cell line. 3. Клеточная линия по п. 1, отличающаяся тем, что она является производной от эмбриональных астроцитов человека. 3. The cell line according to claim 1, characterized in that it is derived from human embryonic astrocytes. 4. Клеточная линия по п. 1, отличающаяся тем, что указанная ксеногенная последовательность нуклеиновой кислоты кодирует биологически активный пептид. 4. The cell line according to claim 1, characterized in that the xenogenic nucleic acid sequence encodes a biologically active peptide. 5. Клеточная линия по п. 3, отличающаяся тем, что указанный биологически активный пептид представляет собой фермент. 5. The cell line according to claim 3, characterized in that the biologically active peptide is an enzyme. 6. Клеточная линия по п. 3, отличающаяся тем, что указанный биологически активный пептид представляет собой связанный с болезнью антиген. 6. The cell line of claim 3, wherein said biologically active peptide is an antigen associated with a disease. 7. Клеточная линия по п. 3, отличающаяся тем, что указанный биологически активный пептид представляет собой тирозин гидроксилазу. 7. The cell line of claim 3, wherein said biologically active peptide is tyrosine hydroxylase. 8. Клеточная линия по п. 1, отличающаяся тем, что указанная нуклеиновая кислота операбельно соединена с промотором транскрипции. 8. The cell line according to claim 1, characterized in that said nucleic acid is operably linked to a transcription promoter. 9. Клеточная линия по п. 7, отличающаяся тем, что она является SVG-ТН клеточной линией. 9. The cell line according to claim 7, characterized in that it is an SVG-TH cell line. 10. Клеточная линия по п. 7, отличающаяся тем, что она способна к экспрессии рhTН/Nео плазмида. 10. The cell line according to claim 7, characterized in that it is capable of expressing phTH / Neo plasmid. 11. Клеточная линия по п. 1, отличающаяся тем, что она дополнительно способна к экспрессии серотонина. 11. The cell line according to claim 1, characterized in that it is additionally capable of expressing serotonin. 12. Трансплантабельная композиция, отличающаяся тем, что она включает в себя клетки из клеточной линии по п. 1 и фармацевтически приемлемый носитель. 12. A transplantable composition, characterized in that it includes cells from the cell line according to claim 1 and a pharmaceutically acceptable carrier. 13. Трансплантабельная композиция по п. 12, отличающаяся тем, что указанные клетки капсулированы при помощи мембраны, непроницаемой для антител. 13. The transplantable composition according to p. 12, characterized in that these cells are encapsulated using a membrane impervious to antibodies. 14. Трансплантабельная композиция по п. 13, отличающаяся тем, что указанная мембрана представляет собой мембрану из геля альгината. 14. The transplantable composition of claim 13, wherein said membrane is an alginate gel membrane. 15. Способ лечения неврологических заболеваний или расстройств, для пациента, который нуждается в таком лечении, отличающийся тем, что указанный способ предусматривает ввод указанному пациенту эффективного количества клеточной линии по п. 1 в фармацевтически приемлемом носителе. 15. A method of treating neurological diseases or disorders for a patient who needs such treatment, characterized in that said method comprises administering to said patient an effective amount of a cell line according to claim 1 in a pharmaceutically acceptable carrier. 16. Способ по п. 15, отличающийся тем, что указанное неврологическое заболевание или расстройство представляет собой болезнь Паркинсона. 16. The method of claim 15, wherein said neurological disease or disorder is Parkinson's disease.
RU98100114/15A 1995-06-06 1996-06-06 Using neuro-derivative embryionic cellular lines for transplantation therapy RU2234338C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/467,958 1995-06-06
US08/467,958 US5753491A (en) 1993-04-13 1995-06-06 Use of neuro-derived fetal cell lines for transplantation therapy

Publications (2)

Publication Number Publication Date
RU98100114A true RU98100114A (en) 2000-01-27
RU2234338C2 RU2234338C2 (en) 2004-08-20

Family

ID=23857846

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98100114/15A RU2234338C2 (en) 1995-06-06 1996-06-06 Using neuro-derivative embryionic cellular lines for transplantation therapy

Country Status (13)

Country Link
US (1) US5753491A (en)
EP (1) EP0832203A4 (en)
JP (1) JPH11506930A (en)
KR (1) KR19990022633A (en)
CN (1) CN1192781A (en)
BR (1) BR9609154A (en)
CA (1) CA2221258A1 (en)
HU (1) HUP9900899A3 (en)
IL (1) IL122337A0 (en)
NZ (1) NZ310048A (en)
RU (1) RU2234338C2 (en)
UA (1) UA61058C2 (en)
WO (1) WO1996039496A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518606D0 (en) * 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
WO1998056393A1 (en) * 1997-06-13 1998-12-17 University Technology Corporation Transplantation of immortalized dopamine cells to improve neurological deficits
US6254865B1 (en) 1997-06-17 2001-07-03 University Technology Corporation Method of treating huntington's disease using HNT neurons
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
WO1999056759A1 (en) 1998-05-07 1999-11-11 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
US20080206206A1 (en) 1998-05-07 2008-08-28 University Of South Florida Bone marrow-derived neuronal cells
US6787356B1 (en) 1998-07-24 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Cell expansion system for use in neural transplantation
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
JP2003524396A (en) * 1999-03-18 2003-08-19 ウェルスタット バイオロジクス コーポレイション Cells, cell populations and methods of making and using them.
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
GB9907243D0 (en) * 1999-03-29 1999-05-26 Reneuron Ltd Therapy
US20030211085A1 (en) * 2000-03-16 2003-11-13 Sanberg Paul R. Cell therapy for chronic stroke
EP1949904A3 (en) 1999-04-27 2008-08-06 Layton Bioscience, Inc. Cell therapy for chronic stroke
US6465215B1 (en) 1999-12-14 2002-10-15 Reneuron Limited Identification of cells for transplantation
US6395546B1 (en) 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
JP2004500824A (en) * 2000-03-09 2004-01-15 クリオ−セル　インターナショナル　インコーポレーティッド Human cord blood as a source of neural tissue for brain and spinal cord repair
ATE342723T1 (en) 2000-04-13 2006-11-15 Univ Texas TREATMENT OF NEURODEGENERATIVE GASTROINTESTINAL DISEASES BY IMPLANTATION OF NEURAL STEM CELLS AND/OR THEIR PROGENTS INTO GASTROINTESTINAL ORGANS
US20040092013A1 (en) * 2001-08-14 2004-05-13 Snyder Evan Y. Method of treating alzheimer's disease with cell therapy
WO2004038018A1 (en) 2002-10-22 2004-05-06 Eisai Co., Ltd. Gene expressed specifically in dopamine-producing neuron precursor cells after termination of division
EP1587545A2 (en) * 2003-01-13 2005-10-26 Mahendra S. Rao Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
JP3996627B2 (en) 2004-07-22 2007-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 Lrp4 / Corin dopaminergic neuron progenitor cell marker
ES2294650T3 (en) 2004-09-30 2008-04-01 Reneuron Limited CELLPHONE LINE.
CN101292031A (en) 2005-08-18 2008-10-22 卫材R&D管理有限公司 Nato3 markers of growing progenitor cell of dopamine-producing neuron
US20100203505A1 (en) 2005-08-18 2010-08-12 Eisai R&D Management Co., Ltd. DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2
CN101466836A (en) 2006-04-11 2009-06-24 卫材R&D管理有限公司 Dopaminergic neuron progenitor cell marker 187A5
US9101570B1 (en) 2009-02-13 2015-08-11 Endocellutions, Inc. Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract
JP6090937B2 (en) 2011-07-27 2017-03-08 国立大学法人京都大学 Novel dopaminergic neural progenitor cell marker

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707448A (en) * 1984-10-04 1987-11-17 The United States Of America As Represented By The Department Of Health And Human Services Immortal line of human fetal glial cells
US5032407A (en) * 1987-01-16 1991-07-16 Ohio University Edison Animal Biotechnology Center Gene transfer using transformed, neodetermined, embryonic cells
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
WO1989009816A1 (en) * 1988-04-12 1989-10-19 Massachusetts Institute Of Technology Method for manipulation of the cell types of eukaryotes
WO1990005781A1 (en) * 1988-11-23 1990-05-31 Baylor College Of Medicine Neural cell transplantation
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5082676A (en) * 1989-05-15 1992-01-21 Hag Gf Aktiengesellschaft Coffee cassette
ES2170096T3 (en) * 1993-04-13 2002-08-01 Us Gov Health & Human Serv USE OF NEURODERIVED FETAL CELLULAR LINES FOR TRANSPLANTATION THERAPY.

Similar Documents

Publication Publication Date Title
RU98100114A (en) USE OF NEURO-DERIVATED EMBRYONIC CELL LINES FOR TRANSPLANTATION THERAPY
Martínez-Serrano et al. Long-term functional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain.
Nikkhah et al. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology
DE69435096T2 (en) COMPOSITION FOR IN VIVO PRODUCTION OF THERAPEUTIC PRODUCTS
Knusel et al. Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain
JP2002504503A5 (en)
WO1999043286A3 (en) Isolated stromal cells for use in the treatment of diseases of the central nervous system
NO933171L (en) Use of molecules targeting cell surface receptors for the treatment of viral diseases
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
US6103226A (en) Genetically engineered cells that produce produce L. Dopa
CA2284079A1 (en) Immunotoxins and methods of inducing immune tolerance
KR900700073A (en) Binding Induction Composition
HUP9800028A2 (en) Multiple-tumor aberrant growth genes
CN1192781A (en) Use of neuro-derived fetal cell lines for tranplantation therapy
Haque et al. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease
Poznansky et al. Insulin: carrier potential for enzyme and drug therapy
Martinez‐Serrano et al. Ex vivo gene transfer of brain‐derived neurotrophic factor to the intact rat forebrain: neurotrophic effects on cholinergic neurons
EP0370171A3 (en) Human nerve growth factor
Christ et al. The application of gene therapy to the treatment of erectile dysfunction
WO1993010234A1 (en) Therapy of central nervous system by genetically modified cells
Wurm et al. Suppression of melanoma development and regression of melanoma in xiphophorine fish after treatment with immune RNA
Khurgel et al. Kindling causes changes in the composition of the astrocytic cytoskeleton
Bernstein et al. Rapid migration of grafted cortical astrocytes from suspension grafts placed in host thoracic spinal cord
JP2003531124A5 (en)
WO1996032137A3 (en) Methods of inducing immune tolerance using immunotoxins